ClinicalTrials.gg
CompletedNCT02261298Updated May 3, 2024

ONO-4538 Phase I Study in Patients With Solid Tumor

A Phase 1 interventional study of ONO-4538 in Advanced Solid Tumors and Recurrent Solid Tumors, sponsored by Ono Pharmaceutical Co. Ltd. Completed at 5 sites in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-05-03.

Sponsored by Ono Pharmaceutical Co. Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Study summary

The objective of this study is to investigate the safety, pharmacokinetics, pharmacology and efficacy of ONO-4538 administered to Korean patients with advanced or recurrent solid tumors who are refractory or intolerant to standard therapy or for whom no appropriate treatment is available.

02

Conditions studied

  • Advanced Solid Tumors
  • Recurrent Solid Tumors
03

In context

Lead sponsor

Ono Pharmaceutical Co. Ltd is the lead sponsor of 63 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The treatment phase has been completed in the ONO-4538-13 study

Exclusion criteria

Exclusion Criteria:

  • The development of PD is identified by the principal or sub investigator according to the guideline (version 1.1) only in case in which the unplanned tumor assessment with diagnostic image is performed in the treatment phase of ONO-4538-13 study.
  • It is determined that continuing the treatment is not appropriate because the worsening of clinical symptoms attributed to disease progression occurs.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    ONO-4538 1mg/kg

    ONO-4538 water-soluble injection, 100 mg/vial, 1mg/kg, 3 times once every 2 weeks in each 6-week cycle

    Drug: ONO-4538

  • Experimental
    ONO-4538 3mg/kg

    ONO-4538 water-soluble injection, 100 mg/vial, 3mg/kg, 3 times once every 2 weeks in each 6-week cycle

    Drug: ONO-4538

  • Experimental
    ONO-4538 10mg/kg

    ONO-4538 water-soluble injection, 100 mg/vial, 10mg/kg, 3 times once every 2 weeks in each 6-week cycle

    Drug: ONO-4538

Interventions

06

What researchers measure

Primary outcomes

  1. Safety outcome: The number of subjects with overall adverse events

    Time frame: Approximately 6 months

  2. Safety outcome: The number of deaths

    Time frame: Approximately 6 months

  3. PK outcome: Cmax of ONO-4538

    Time frame: Approximately 10 months

  4. Efficacy outcome: Response rate

    Time frame: Approximately 6 months

  5. Efficacy outcome: Progression free survival

    Time frame: Approximately 6 months

07

Study locations

5 sites
  • Seongnam-si Clinical Site 105
    Seongnam-si, Gyeonggi-do, Korea, Republic of
  • Seoul Clinical Site 101
    Seoul, Korea, Republic of
  • Seoul Clinical Site 102
    Seoul, Korea, Republic of
  • Seoul Clinical Site 103
    Seoul, Korea, Republic of
  • Seoul Clinical Site 104
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Lee KW, Lee DH, Kang JH, Park JO, Kim SH, Hong YS, Kim ST, Oh DY, Bang YJ. Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors. Oncologist. 2018 Feb;23(2):155-e17. doi: 10.1634/theoncologist.2017-0528. Epub 2017 Nov 20. PubMed 29158363 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2014 to primary completion in Jun 2015, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2014
First posted
Oct 10, 2014
StartActual
Oct 2014
Primary completionActual
Jun 2015
CompletionActual
Apr 2020
Last update
May 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02261298
Responsible party
Sponsor
First posted
Oct 10, 2014
Start date
Oct 2014
Primary completion
Jun 2015
Completion
Apr 2020
Last update
May 3, 2024

Study contacts

Mitsunobu Tanimoto
study director · Ono Pharmaceutical Co. Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion